Zinc Gluconate Compared to Placebo for Improving Blood Sugar Control in Adults with Prediabetes Over One Year

What this Trial Is About

This trial is studying adults with prediabetes to evaluate how zinc supplementation affects blood sugar control, specifically measuring fasting glucose levels and hemoglobin A1c HbA1c. The trial tests whether taking zinc gluconate daily for one year leads to greater improvements in these measures compared to a placebo. The study is a double-blind, randomized clinical trial involving 200 prediabetic participants aged 18 to 80 years. Participants are randomly assigned to receive either zinc gluconate 30 mg daily or a placebo for 12 months. The study involves three clinic visits at baseline, 6 months, and 12 months, where blood and urine samples are collected to measure zinc levels, glucose homeostasis markers including fasting glucose, HbA1c, insulin levels, and a 2-hour oral glucose tolerance test OGTT. Participants will take one tablet daily, and adherence will be monitored using pill counts and daily logbooks. Throughout the study, participants undergo medical history reviews, physical exams, and questionnaires to assess diet and health status. Laboratory tests include blood counts, metabolic panels, thyroid function, and lipid profiles. Researchers will compare the effects of zinc versus placebo on glucose control at 6 and 12 months. Participants safety and adherence are closely monitored, and the total participation lasts one year.

Effect of Zinc on Glucose Homeostasis